AeroVanc developer Savara Pharmaceuticals has acquired Serendex Pharmaceuticals, which is developing Molgradex inhaled granulocyte-macrophage colony-stimulating factor (molgramostim) for the treatment of autoimmune pulmonary alveolar proteinosis (PAP). Serendex announced in September 2015 that it was initiating a Phase 2 clinical trial of Molgradex, which is delivered via the PARI eFlow nebulizer system.
Earlier this year, Savara announced that it had raised $20 million for a Phase 3 clinical trial of its AeroVanc vancomycin DPI, which the FDA has granted Orphan, Fast Track, and QIDP designations. The company is developing AeroVanc for the treatment of persistent MRSA lung infections in cystic fibrosis patients.
Savara CEO Rob Neville commented, “The acquisition is a transformational milestone for Savara, expanding our pipeline of orphan respiratory drugs with an exciting product for a highly debilitating disease with no approved medicinal treatments. Molgradex is a beautiful fit with our lead product, AeroVanc, and has the potential to be a truly disease-modifying treatment for PAP based on clinical evidence from academically sponsored pilot studies and case reports on inhaled GM-CSF.”
Read the Savara press release.
